Drug Profile
Tylerdipine Hydrochloride - Sihuan Pharmaceutical Holdings Group
Alternative Names: 5660; KBP 5660Latest Information Update: 28 Nov 2021
Price :
$50
*
At a glance
- Originator Sihuan Pharmaceutical Holdings Group; XuanZhu Pharma
- Developer Nanjing Medical University; Sihuan Pharmaceutical Holdings Group
- Class Antihypertensives; Small molecules
- Mechanism of Action L-type calcium channel agonists; T type calcium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Hypertension
Most Recent Events
- 28 Nov 2021 No recent reports of development identified for phase-I development in Hypertension in China (PO)
- 14 Jul 2020 Tylerdipine Hydrochloride - Sihuan Pharmaceutical Holdings Group is available for licensing as of 08 Jul 2020. http://www.xuanzhupharm.com/index.php?m=content&c=index&a=lists&catid=527 (XuanZhu Pharma pipeline, July 2020)
- 27 Oct 2018 Phase I development is ongoing in China